ADMA Biologics (ADMA)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $2.4B, ADMA Biologics's free cash flow of $28M (fiscal 2025) would need to grow about 24% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 2 years.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from ADMA Biologics's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from ADMA's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from ADMA Biologics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $81M | $154M | $258M | $426M | $510M |
| Net income | -$72M | -$66M | -$28M | $198M | $147M |
| Free cash flow | -$126M | -$73M | $4M | $110M | $28M |
| EPS (diluted) | -$0.51 | -$0.33 | -$0.13 | $0.81 | $0.60 |
| Operating margin | -72.1% | -25.5% | 8.4% | 32.6% | 37.5% |
Where the revenue comes from
Revenue by segments, fiscal 2025. Every breakdown, year by year.
Superinvestors who own ADMA
From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Stanley Druckenmiller Duquesne Family Office |
Added | $23M | 0.45% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | $13M | 0.00% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
New position | $617,949 | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by ADMA Biologics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 5, 2026 | Steve Elms |
7,000 | $15.67 | $109,690 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ADMA trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
What growth does ADMA Biologics's stock price imply?
At a market value of $2.4B, ADMA Biologics would need its free cash flow to grow about 24% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 2 years its free cash flow grew 163% a year.
Are ADMA Biologics insiders buying the stock?
1 open-market insider purchase of ADMA in the last 12 months, from SEC Form 4 filings.
Which superinvestors own ADMA Biologics?
3 of the superinvestors Investingly tracks hold ADMA in their latest 13F, including Stanley Druckenmiller, Cliff Asness, Joel Greenblatt.
Companies like ADMA Biologics
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.